The Role of 18F-FDG&68Ga-FAPI PET/CT in the Assessment of Conversion Therapy Efficacy in Gastric Cancer with Peritoneal Metastasis.

Trial statusRecruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age18+
SponsorRuijin Hospital

About this trial

This study aims to investigate the value of 18F-FDG\&68Ga-FAPI PET/CT in evaluating the outcome of conversion therapy and the prognosis of people with peritoneal metastases from gastric cancer.

Eligibility criteria

Qualifiers

Histologically confirmed gastric adenocarcinoma with no history of resection of primary or metastatic lesions

Peritoneal metastases of gastric cancer requiring laparoscopy for definitive diagnosis without gastric outflow tract obstruction and intestinal obstruction

Patients voluntarily enrolled in this study by signing an informed consent form

Age ≥ 18 years

Disqualifiers

Signs of distant metastases other than peritoneal metastases at enrolment

Pregnant or breastfeeding women.

Patients with a history of other malignant diseases in the last 5 years, except cured skin cancer and carcinoma in situ of cervix

Severe mental disease, uncontrolled epilepsy, or central nervous system disease

Trial design

Treatments tested in this trial

  • Not listed

Trial groups

30 Participants
are grouped into 1 trial group

Sponsors and collaborators